An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...
Abstract: Ruthenium (Ru) etch mechanisms, challenges, and progress are reviewed. Conventional Ru etch chemistries are limited and have substrate compatibility or toxic-material-release concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results